Microcystic Lymphatic Malformation
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Palvella TherapeuticsWAYNE, PA
2 programsPTX-022PHASE_21 trial
QTORIN 3.9% Rapamycin Anhydrous GelPHASE_31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
Palvella TherapeuticsQTORIN 3.9% Rapamycin Anhydrous Gel
Palvella TherapeuticsPTX-022
Clinical Trials (2)
Total enrollment: 63 patients across 2 trials
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Start: Jul 2024Est. completion: Jul 202651 patients
Phase 3Active Not Recruiting
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Start: Jan 2022Est. completion: Dec 202212 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.